All Articles by Author:


Diosgenin Derivatives Developed from Pd(ii) Catalysed Dehydrogenative Coupling Exert an Effect on Breast Cancer Cells by Abrogating Their Growth and Facilitating Apoptosis via Regulating...

[Dalton Transactions] Based on the pharmacological importance of diosgenin, the obtained derivatives were exposed to study their effect on breast cancer cells where they significantly reduced the growth of cancer cells and left non-malignant breast epithelial cells unaffected.

Clinically Relevant CHK1 Inhibitors Abrogate Wild-Type and Y537S Mutant ERα Expression and Proliferation in Luminal Primary and Metastatic Breast Cancer Cells

[Journal of Experimental & Clinical Cancer Research] The authors evaluated if kinases could be new targets for the treatment of luminal primary and metastatic breast cancers.

Nrf2 and NF-κB/NLRP3 Inflammasome Pathways Are Involved in Prototheca bovis Infections of Mouse Mammary Gland Tissue and Mammary Epithelial Cells

[Free Radical Biology and Medicine] Investigators characterized how Prototheca bovis induced inflammatory responses in mouse mammary gland tissue and mammary epithelial cells.

Modified Bovine Milk Exosomes for Doxorubicin Delivery to Triple-Negative Breast Cancer Cells

[ACS Applied Bio Materials] Scientists described the use of two chemical modifications, incorporating a neuropilin receptor agonist peptide and a hypoxia-responsive lipid for targeting and release of an encapsulated drug from bovine milk exosomes toTNBC cells.

Dinaciclib Inhibits the Stemness of Two Subtypes of Human Breast Cancer Cells by Targeting the FoxM1 and Hedgehog Signaling Pathway

[Oncology Reports] Investigators aimed to examine the stemness‑inhibitory effects of dinaciclib in MCF‑7 and HCC‑1806 breast cancer cells.

Breast Cancer in the Era of Integrating “Omics” Approaches

[Oncogenesis] The authors investigated the correlation between different “omics” datasets and to define the new important key pathway and upstream regulators in breast cancer.


Truqap Plus Faslodex Approved in the EU for Patients with Advanced ER-Positive Breast Cancer

[AstraZeneca] AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the European Union (EU) for the treatment of adult patients with ER-positive, HER2‑negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN-alterations following recurrence or progression on or after an endocrine-based regimen.

Breast Cancer Exploits Neural Signaling Pathways for Bone-to-Meninges Metastasis

[Science] Scientists applied a combination of intravital and ex vivo three-dimensional confocal microscopy, micro–computed tomography, and histologic analyses to mouse models of bone-metastatic breast cancer and leptomeninges (LM) metastasis,. They demonstrated that breast cancer cells could traffic to the LM from the bone marrow through abluminal emissary vein migration.

RUVBL1/2 Blockade Targets YTHDF1 Activity to Suppress m6A-Dependent Oncogenic Translation and Colorectal Tumorigenesis

[Cancer Research] Investigators employed a CRISPR/Cas9 screening strategy that revealed RUVBL1 and RUVBL2 as putative targets. Loss of RUVBL1/2 preferentially impaired the growth of YTHDF1-high colorectal cancer (CRC) cells, patient-derived primary CRC organoids, and subcutaneous xenografts.